Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated tau in the Evaluation of 1,016 Individuals for Suspected Dementia

Manuscript Number: 

18-0548R2

Author(s): 
Matthew Casadei, Lawrence S. Honig, Richard Mayeux, Guy M. McKhann II, Leonardo Tariciotti, Andrew F. Teich, Giuseppe Tosto

Disclosures

Matthew Casadei

  • Nothing to Disclose

Lawrence S. Honig

  • Consulting Fees:
    Consulting for Eisai, Eli Lilly, Miller Communications, State of Texas, all less than $5,000 per annum.
    Grants
    • Agency: 
      Biogen-Idec
      Dates: 
      current
    • Agency: 
      Bristol-Myer Squibb
      Dates: 
      current
    • Agency: 
      Eisai
      Dates: 
      current
    • Agency: 
      Eli Lilly
      Dates: 
      current
    • Agency: 
      Genentech
      Dates: 
      current
    • Agency: 
      Roche
      Dates: 
      current
    • Agency: 
      vTv Therapeutics
      Dates: 
      current
    • Agency: 
      Lundbeck
      Dates: 
      2010-2017
    • Agency: 
      Abbvie
      Dates: 
      current

Richard Mayeux

  • Nothing to Disclose

Guy M. McKhann II

  • Nothing to Disclose

Leonardo Tariciotti

  • Nothing to Disclose

Andrew F. Teich

  • Nothing to Disclose

Giuseppe Tosto

  • Nothing to Disclose